Replies to post #206638 on Avid Bioservices Inc (CDMO)

[biopharm]

wrong again and Robert Garnick exact words were stated as:

Having personally been involved in the evaluation of over 30 Phase II trials over my career, none of which ever achieved statistical significance, including many of today's blockbuster biotech products

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110901862&txt2find=garnick

A fact that lung cancer is the #1 killer of all cancers

Bavituximab + Docetaxel in phase IIb NSCLC:

1) A fact that no other phase II trial beat MOS by 109%+ in NSCLC

2) A fact that no other phase II trial beat MOA by 60%+ in NSCLC

3) A fact that the FDA has never approved a phase III trial based on any statistically signifianct results as compelling as Bavituximab + Docetaxel and as conclusive evidence surfaced, making it well known that sabotage occurred.

Rather interesting that the 3mg arm was never touched and why? Many believe it is because it was assumed that the share price was supposed to go north of $5+ even further and Oxford loan ($15M) wouldn't of been able to be paid back (as Peregrine would have been restricted and not been able to have used ATM) and forced into bankruptcy as you even predicted on your 1st ever post the night of Black Monday)

Funny how the tables have turned and why would Bristol Myers Squibb actually come out and publicly admit that patients live longer when low levels of MDSC's were reported in those same patients and high levels of MDSC's led to death?

No other Big Pharma can ever, ever claim a 40% reduction in MDSC's such that Peregrine has officially, publicly reported right here:

Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma

Feb 9, 2015
...
..

Moreover, cells that suppress the immune system from recognizing tumors, such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone. These data, further validating the immune-stimulatory mechanism of bavituximab, are outlined in an oral and poster presentation by Bruce Freimark, Ph.D., director, preclinical oncology research at Peregrine, to be made at the Keystone Tumor Immunology: Multidisciplinary Science Driving Combination Therapy meeting being held February 8-13, 2015 in Banff, Alberta, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
..
..

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=895363

[Frustrated]

It is amazing how something clearly showing proof of a lie, mistake etc... is thrown away as rubbish, yet the false statements about someone sabotaging the botched trial which has not been proven yet is stated as a fact (yes it has been almost 2.5 years!). Again if sabotage was a fact the stock would not be at $1.28 and if it is indeed true than how do you suppose they will not sabotage an even more important trial. Yeah that's the ticket.

Even more silly is the idea that the can't release news because of the lawsuits or that they are waiting on the European patent. If the the US patent PR would increase the share price wouldn't you think a respected BOD would release the US patent news and then wait until the European patent is granted and then PR that.? It would be getting two PR's for the price of one news. It is simple business 101.

PPHM THE COMPANY THAT HAS BEEN LOOKING TO ADD QUALIFIED BOARD MEMBERS SINCE 2010 YET CAN'T FIND A MATCH WITH THE CURRENT CREDENTIALS OF OUR BOD AND THEIR PENNY STOCK PEDIGREE. 75% OF THE BOARD HAS TIES TO PATRIOTIC SCIENTIFIC WHICH NOW TRADES AT 5 PENNIES YET THE COMPANY CLAIMS TO HAVE AN INDEPENDENT BOD.

PPHM THE COMPANY WHOSE CEO IN MARCH 2014 TALKED ABOUT A PARTNERSHIP COMING TO FRUITION IN UPCOMING YEAR. IT IS NOW FEBRUARY 17, 2015, 48 days past the year 2014. CREDIBILITY IS AN ISUUE. ALL IMO.